B+
Bull case
30%
Probability
Target price
$43.00
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
QURE
uniQureCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-11-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-11-05
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+89.7
Score
AI commentary
Early T+1 tone is mixed rather than unreservedly bullish. The company release confirms meaningful regulatory progress and longer projected runway, but Q3 revenue missed a reported FactSet estimate. QURE closed November 4 at $23.03, down 3.52% according to MarketScreener, after an initially positive premarket reaction reported by Investing.com; that reversal should not be attributed to a single cause without stronger evidence. Published EPS-consensus figures disagree, and verified post-print analyst target revisions are unavailable. https://www.marketscreener.com/quote/stock/UNIQURE-N-V-15712155/news/ https://www.investing.com/news/transcripts/earnings-call-transcript-uniqure-posts-q3-2026-eps-beat-as-fda-review-advances-93CH-4999868
RankAlpha Sentiment Codex - 2026-11-05
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventAMT-130 confirmatory-study screeningHigh impact
Management expects U.S. patient screening by year-end 2026 for an approximately 200-patient, standard-of-care-controlled study. Timely initiation matters to the accelerated-approval pathway, though enrollment and execution remain uncertain. [#SEC-8K-2026-11-04]
2027-05-01eventAMT-130 FDA decisionHigh impact
The Q3 earnings release confirmed FDA Priority Review of the Huntington's disease BLA and a May 1, 2027 target action date. Approval would materially change the commercial outlook, but acceptance for review is not approval. [#8-K-2026-11-04] [#SEC-8K-2026-11-04]
2027-06-30catalystAMT-260 epilepsy dataHigh impact
After completing enrollment of the seven-patient second dose cohort, uniQure expects updated Phase I/IIa results in the first half of 2027. This could diversify a thesis currently dominated by AMT-130. [#SEC-8K-2026-11-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-11-05 • Updated nightlySource: Internal modelMethodology